ARA-290
Also known as: Cibinetide
Molecular Identifiers
Overview
Synthetic 11-amino acid peptide derived from erythropoietin (EPO), designed to selectively activate the innate repair receptor (IRR) without erythropoietic effects. With a molecular weight of approximately 1,257.4 Da, it possesses neuroprotective, anti-inflammatory, and tissue repair properties without stimulating red blood cell production.
QEQLERALNSS Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser Half-life
~2-3 minutes (IV), longer SC
Administration Route
Subcutaneous
Category
Healing & Recovery
Mechanism of Action
- Selective activation of the innate repair receptor (IRR/EPOR-βcR)
- Neuroprotection and peripheral nerve fiber repair
- Anti-inflammatory action via suppression of pro-inflammatory cytokines
- Promotion of tissue repair and cellular regeneration
- Modulation of the innate immune response
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 2-4 mg per injection |
| Frequency | Once daily |
| Timing | Morning or as directed |
| Duration | 4-12 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Headache
- Mild nausea
- Dizziness
- Injection site pain
Presentations & Preparation
Vials of ARA-290 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on ARA-290.
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A
Related Peptides
BPC-157
250-500 mcg per injection · 1-2 times daily
Cartalax
5-10 mg per day · Once daily
GHK-Cu
1-3 mg per injection · Once daily or every other day
LL-37
50-200 mcg per injection · Once daily
MGF
200-400 mcg per injection · Once daily (MGF) or 2-3 times per week (PEG-MGF)
TB-500
2-5 mg per injection · Twice per week